BioAtla BCAB 深 滬
已收盤 08-07 16:00:00 美东时间
3.46
+0.130
+3.90%
華盛通- 最 高3.7083
- 今 開3.33
- 成交量 3.71万股
- 最 低 3.2738
- 昨 收 3.33
- 總市值 574.21万
- 52周最高 71.50
- 市盈率 靜 --
- 換手率 2.23%
- 52周最低 3.12
- 委 比 0.00%
- 總股本 165.96万
- 歷史最高 3831.50
- 量 比 0.91
- 振 幅 13.05%
- 歷史最低 3.2738
- 每 手 1
- 風險率 14.99%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress
Context Therapeutics Inc. reported its Q2 2026 financial results, with cash reserves of $43 million expected to fund operations into Q4 2027. The company prioritized its CTIM-76 and CT-202 clinical programs, with initial data expected in Q2 2027. CTIM-76 showed encouraging interim results in platinum-resistant ovarian cancer patients, while CT-202 is set to begin its first patient dosing in Q3 2026. CT-95 development was discontinued. R&D expense...
08-05 20:14
Context Therapeutics Announces Amendment To Its Exclusive License Agreement With BioAtla To Remove All Future Milestone And Royalty Obligations For CT-202 In Exchange For A $4.5M Upfront Payment And A Final $2M Payment Due By August 1
Phase 1 initiation for CT-202 trial expected in third quarter of 2026
05-18 18:49
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
Context Therapeutics amended its license agreement with BioAtla, removing future milestones and royalties for CT-202 in exchange for a $4.5 million upfront payment and a $2.0 million payment by August 1, 2026. CT-202, a Nectin-4 x CD3 T cell engager, targets Nectin-4, a protein overexpressed in various solid tumors. Its pH-dependent design aims to minimize adverse effects. Phase 1 trials for CT-202 are expected to begin in Q3 2026.
05-18 10:45
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Cyclerion Therapeutics (NASDAQ:CYCN) shares rose 307.1% to $6.31 durin...
04-02 01:06
BioAtla Begins Strategic Review Following 2025 Results
BioAtla ( ($BCAB) ) has shared an update. On March 31, 2026, BioAtla reported f...
04-01 07:46
BioAtla Q4 EPS $(0.16) Beats $(0.30) Estimate, Sales $2.000M Beat $700.000K Estimate
BioAtla (NASDAQ:BCAB) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.30) by 47.19 percent. This is a 46.67 percent increase over losses of $(0.30) per share from the same
04-01 05:03
BioAtla shares are trading lower after the company announced a 50-for-1 share consolidation.
BioAtla shares are trading lower after the company announced a 50-for-1 share c...
04-01 04:20
BioAtla to implement 50-for-1 share consolidation
BioAtla (BCAB) on Tuesday said it will carry out a 50-for-1 share consolidation of its common stock, effective April 6, 2026, as it seeks to raise its share price to meet the $1.00 minimum bid require...
04-01 04:12
